首页> 美国卫生研究院文献>other >Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein
【2h】

Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein

机译:类似于病毒刺突蛋白的肽抑制重症急性呼吸综合征相关冠状病毒(SARS-CoV)感染

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) is the cause of an atypical pneumonia that affected Asia, North America and Europe in 2002–2003. The viral spike (S) glycoprotein is responsible for mediating receptor binding and membrane fusion. Recent studies have proposed that the carboxyl terminal portion (S2 subunit) of the S protein is a class I viral fusion protein. The Wimley and White interfacial hydrophobicity scale was used to identify regions within the CoV S2 subunit that may preferentially associate with lipid membranes with the premise that peptides analogous to these regions may function as inhibitors of viral infectivity. Five regions of high interfacial hydrophobicity spanning the length of the S2 subunit of SARS-CoV and murine hepatitis virus (MHV) were identified. Peptides analogous to regions of the N-terminus or the pre-transmembrane domain of the S2 subunit inhibited SARS-CoV plaque formation by 40–70% at concentrations of 15–30 μM. Interestingly, peptides analogous to the SARS-CoV or MHV loop region inhibited viral plaque formation by >80% at similar concentrations. The observed effects were dose-dependent (IC50 values of 2–4 μM) and not a result of peptide-mediated cell cytotoxicity. The antiviral activity of the CoV peptides tested provides an attractive basis for the development of new fusion peptide inhibitors corresponding to regions outside the fusion protein heptad repeat regions.
机译:严重的急性呼吸系统综合症相关冠状病毒(SARS-CoV)是引起非典型肺炎的原因,该肺炎在2002-2003年影响了亚洲,北美和欧洲。病毒刺突(S)糖蛋白负责介导受体结合和膜融合。最近的研究提出,S蛋白的羧基末端部分(S2亚基)是I类病毒融合蛋白。使用Wimley和White界面疏水性标度来鉴定CoV S2亚基内可能优先与脂质膜结合的区域,前提是与这些区域类似的肽可以起病毒感染性抑制剂的作用。确定了跨越SARS-CoV S2亚基和鼠肝炎病毒(MHV)的五个高界面疏水性区域。与S2亚基的N末端或跨膜前结构域相似的肽在15-30μM的浓度下可抑制SARS-CoV噬菌斑形成40-70%。有趣的是,与SARS-CoV或MHV环区相似的肽在相似浓度下抑制病毒噬斑形成> 80%。观察到的影响是剂量依赖性的(IC50值为2-4μM),而不是肽介导的细胞毒性的结果。测试的CoV肽的抗病毒活性为开发新的融合肽抑制剂提供了诱人的基础,该抑制剂对应于融合蛋白七肽重复区以外的区域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号